Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
for Urothelial Cancer
Sites in Lexington +32 more locations
Sponsor: Bristol-Myers Squibb
Sex: All·Age: 18+
Code: NCT07106762·Phase 2, Phase 3·Recruiting·Listed Aug 2025